NCT04827953CompletedPhase 1
Study to Evaluate the Safety and Efficacy of Treatment with NLM-001 before Standard Chemotherapy plus Zalifrelimab in Patients with Advanced Pancreatic Cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 May 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- First submitted
- 9 Oct 2024
- Start date
- 3 Sept 2021
- Lead sponsor
- Nelum Corp.
- Diseases
- Pancreatic cancer
- NCT number
- NCT04827953
- EU CT number
- 2024-518852-22-00
- EudraCT number
- 2020-004932-52
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 28
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Hospital Universitario Donostia Coordinator of this site? Confirm its status | Donostia | Spain | Completed |
| Hospital Universitario Virgen de la Victoria Coordinator of this site? Confirm its status | Málaga | Spain | Completed |
| Hospital Universitario Marqués de Valdecilla Coordinator of this site? Confirm its status | Santander | Spain | Completed |
| Complexo Hospitalario Universitario De Santiago Coordinator of this site? Confirm its status | Santiago de Compostela | Spain | Completed |
| Hospital Universitario Miguel Servet Coordinator of this site? Confirm its status | Zaragoza | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.